Summary
MD is aggressively expanding its medical service offerings.
The business model of acquiring private practices is solid.
MD has vastly underperformed the market, and is worth keeping an eye on.
The capital allocation priorities going forward concern me.
The market has been rough over the past month, and I’m looking to put some cash to use. But where? I’ve been studying the healthcare sector quite a lot lately, looking for undervalued companies providing necessary medical services, equipment, and pharmaceuticals. This seems like a good idea to me regardless of what the market is doing, but especially now that investor uncertainty seems to be taking hold of the overall narrative. Value and safety are the name of the game.
I started watching Mednax, Inc. (NYSE:MD) recently because of the increasing revenues, stable cashflow, and declining stock price. There might be something here. The company reported Q3 earnings on Thursday, November 1st, and the market was not happy with the results. Mednax reported adjusted earnings of $0.94 a share, missing analyst estimates of $0.97.


